{"id":"https://openalex.org/W2902996841","doi":"https://doi.org/10.1016/j.bmcl.2018.11.058","title":"Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) \u2013 Part 1","display_name":"Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) \u2013 Part 1","publication_year":2018,"publication_date":"2018-12-01","ids":{"openalex":"https://openalex.org/W2902996841","doi":"https://doi.org/10.1016/j.bmcl.2018.11.058","mag":"2902996841","pmid":"https://pubmed.ncbi.nlm.nih.gov/30554956"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmcl.2018.11.058","doi":"https://doi.org/10.1016/j.bmcl.2018.11.058","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2018.11.058","pdf_url":"https://www.sciencedirect.com/science/article/pii/S0960894X1830934X/pdf","source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.sciencedirect.com/science/article/pii/S0960894X1830934X/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027115821","display_name":"Joanne Osborne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Joanne Osborne","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059606387","display_name":"Kristian Birchall","orcid":"https://orcid.org/0000-0001-9992-2555","observed_orcids":["https://orcid.org/0000-0001-9992-2555"]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kristian Birchall","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035789499","display_name":"Denise J. Tsagris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Denise J. Tsagris","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Stephen J. Lewis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen J. Lewis","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065201672","display_name":"Ela Smiljanic-Hurley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ela Smiljanic-Hurley","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110847838","display_name":"Debra L. Taylor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Debra L. Taylor","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Alison Levy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alison Levy","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054181982","display_name":"Dario R. Alessi","orcid":"https://orcid.org/0000-0002-2140-9185","observed_orcids":["https://orcid.org/0000-0002-2140-9185"]},"institutions":[{"id":"https://openalex.org/I177639307","display_name":"University of Dundee","ror":"https://ror.org/03h2bxq36","country_code":"GB","type":"education","lineage":["https://openalex.org/I177639307"]},{"id":"https://openalex.org/I4210110201","display_name":"MRC Protein Phosphorylation and Ubiquitylation Unit","ror":"https://ror.org/01zg1tt02","country_code":"GB","type":"facility","lineage":["https://openalex.org/I177639307","https://openalex.org/I4210087105","https://openalex.org/I4210110201","https://openalex.org/I90344618"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dario R. Alessi","raw_affiliation_strings":["The MRC Protein Phosphorylation Unit, The Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The MRC Protein Phosphorylation Unit, The Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK","institution_ids":["https://openalex.org/I177639307","https://openalex.org/I4210110201"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032388950","display_name":"Edward G. McIver","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I109541847","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I109541847"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Edward G. McIver","raw_affiliation_strings":["LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, UK","institution_ids":["https://openalex.org/I109541847"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5032388950"],"corresponding_institution_ids":["https://openalex.org/I109541847"],"apc_list":{"value":3880,"currency":"USD","value_usd":3880},"apc_paid":{"value":3880,"currency":"USD","value_usd":3880},"fwci":0.8206,"has_fulltext":true,"cited_by_count":17,"citation_normalized_percentile":{"value":0.69782326,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"29","issue":"4","first_page":"668","last_page":"673"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.8568999767303467,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.8568999767303467,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.04100000113248825,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.03350000083446503,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lrrk2-inhibitors","display_name":"LRRK2 inhibitors","score":0.8640000224113464},{"id":"https://openalex.org/keywords/leucine-rich-repeat-kinase-2","display_name":"leucine-rich repeat kinase 2","score":0.9290000200271606},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hit-to-lead","display_name":"hit-to-lead optimization","score":0.878000020980835},{"id":"https://openalex.org/keywords/kinase-inhibitor-selectivity","display_name":"kinase selectivity","score":0.921999990940094},{"id":"https://openalex.org/keywords/heterocyclic-substitution","display_name":"heterocyclic substitution","score":0.6570000052452087},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/dopaminergic-neuron-damage","display_name":"dopaminergic neuron damage","score":0.7509999871253967}],"concepts":[{"id":"https://openalex.org/C2780427247","wikidata":"https://www.wikidata.org/wiki/Q409961","display_name":"LRRK2","level":4,"score":0.8893746137619019},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6726834774017334},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.6222840547561646},{"id":"https://openalex.org/C2777752112","wikidata":"https://www.wikidata.org/wiki/Q903238","display_name":"Lead compound","level":3,"score":0.5463760495185852},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5318552851676941},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.5195765495300293},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5145270228385925},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.4417630732059479},{"id":"https://openalex.org/C118792377","wikidata":"https://www.wikidata.org/wiki/Q108584245","display_name":"Selectivity","level":3,"score":0.42833685874938965},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.41139742732048035},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3392764925956726},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3211343288421631},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3067821264266968},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.24848699569702148},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.20132127404212952},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18318185210227966},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.07009431719779968},{"id":"https://openalex.org/C161790260","wikidata":"https://www.wikidata.org/wiki/Q82264","display_name":"Catalysis","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000071158","descriptor_name":"Leucine-Rich Repeat Serine-Threonine Protein Kinase-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.bmcl.2018.11.058","doi":"https://doi.org/10.1016/j.bmcl.2018.11.058","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2018.11.058","pdf_url":"https://www.sciencedirect.com/science/article/pii/S0960894X1830934X/pdf","source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:30554956","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30554956","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry letters","raw_type":"Journal Article"},{"id":"pmh:oai:discovery.dundee.ac.uk:openaire/c57b5ae0-cc95-488e-b8ba-8c8cbd56bab8","doi":null,"is_oa":true,"landing_page_url":"https://discovery.dundee.ac.uk/en/publications/c57b5ae0-cc95-488e-b8ba-8c8cbd56bab8","pdf_url":null,"source":{"id":"https://openalex.org/S4306400523","display_name":"Discovery Research Portal (University of Dundee)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177639307","host_organization_name":"University of Dundee","host_organization_lineage":["https://openalex.org/I177639307"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Osborne, J, Birchall, K, Tsagris, D J, Lewis, S J, Smiljanic-Hurley, E, Taylor, D L, Levy, A, Alessi, D & McIver, E G 2019, 'Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1', Bioorganic & Medicinal Chemistry Letters, vol. 29, no. 4, pp. 668-673. https://doi.org/10.1016/j.bmcl.2018.11.058","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.bmcl.2018.11.058","doi":"https://doi.org/10.1016/j.bmcl.2018.11.058","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2018.11.058","pdf_url":"https://www.sciencedirect.com/science/article/pii/S0960894X1830934X/pdf","source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2035955455","display_name":null,"funder_award_id":"H-1701","funder_id":"https://openalex.org/F4320320021","funder_display_name":"Parkinson's UK"},{"id":"https://openalex.org/G6291034611","display_name":"Understanding Signalling Pathways Mutated in Inherited Disorders","funder_award_id":"MC_UU_00018/1","funder_id":"https://openalex.org/F4320334626","funder_display_name":"Medical Research Council"}],"funders":[{"id":"https://openalex.org/F4320313480","display_name":"LifeArc","ror":"https://ror.org/01dqb0q37"},{"id":"https://openalex.org/F4320320021","display_name":"Parkinson's UK","ror":"https://ror.org/02417p338"},{"id":"https://openalex.org/F4320334626","display_name":"Medical Research Council","ror":"https://ror.org/03x94j517"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2902996841.pdf","grobid_xml":"https://content.openalex.org/works/W2902996841.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1967234247","https://openalex.org/W1986961354","https://openalex.org/W1991732882","https://openalex.org/W2016575780","https://openalex.org/W2021052428","https://openalex.org/W2031345305","https://openalex.org/W2041890817","https://openalex.org/W2062458432","https://openalex.org/W2063127941","https://openalex.org/W2066123026","https://openalex.org/W2074657560","https://openalex.org/W2100300726","https://openalex.org/W2106350754","https://openalex.org/W2116877425","https://openalex.org/W2120233435","https://openalex.org/W2126852807","https://openalex.org/W2127073449","https://openalex.org/W2148928480","https://openalex.org/W2165355919","https://openalex.org/W2317683727","https://openalex.org/W2326172157","https://openalex.org/W4210952882"],"related_works":["https://openalex.org/W2896574157","https://openalex.org/W2973230134","https://openalex.org/W2593373447","https://openalex.org/W2021052428","https://openalex.org/W4213353411","https://openalex.org/W4310948932","https://openalex.org/W2344692802","https://openalex.org/W4387432462","https://openalex.org/W1994597724","https://openalex.org/W4319662261"],"abstract_inverted_index":{"Parkinson's":[0],"disease":[1,31],"is":[2],"a":[3,35,97,111,153],"relatively":[4],"common":[5],"neurological":[6],"disorder":[7],"with":[8,11,118],"incidence":[9],"increasing":[10],"age.":[12],"Present":[13],"treatments":[14],"merely":[15],"alleviate":[16],"the":[17,23,26,42,56,67,70,77,85,126,133,141,145],"symptoms":[18],"and":[19,50,135],"do":[20],"not":[21],"alter":[22],"course":[24],"of":[25,30,60,69,84,100,116,123],"disease,":[27],"thus":[28,73],"identification":[29],"modifying":[32],"therapies":[33],"represents":[34],"significant":[36],"unmet":[37],"medical":[38],"need.":[39],"Mutations":[40],"in":[41],"LRRK2":[43,62,74],"gene":[44],"are":[45,64],"risk-factors":[46],"for":[47,66,157],"developing":[48],"PD":[49],"it":[51],"has":[52],"been":[53],"hypothesized":[54],"that":[55],"increased":[57],"kinase":[58,136],"activity":[59],"certain":[61],"mutants":[63],"responsible":[65],"damage":[68],"dopaminergic":[71],"neurons,":[72],"inhibitors":[75],"offer":[76],"potential":[78],"to":[79,110,130,140,152],"target":[80],"an":[81],"underlying":[82],"cause":[83],"disease.":[86],"In":[87],"this":[88],"communication,":[89],"we":[90],"describe":[91],"hit-to-lead":[92],"medicinal":[93],"chemistry":[94],"program":[95],"on":[96],"novel":[98],"series":[99,115,149],"5-azaindazoles.":[101],"Compound":[102],"1,":[103],"obtained":[104],"from":[105],"high-throughput":[106],"screening":[107],"was":[108,150],"optimized":[109],"highly":[112],"potent,":[113],"selective":[114],"molecules":[117],"promising":[119],"DMPK":[120],"properties.":[121,147],"Introduction":[122],"heterocycles":[124],"at":[125],"3-position":[127],"were":[128],"found":[129],"significantly":[131],"increase":[132],"potency":[134],"selectivity,":[137],"whilst":[138],"changes":[139],"4-chlorobenzyl":[142],"group":[143],"improved":[144],"physicochemical":[146],"Our":[148],"licensed":[151],"major":[154],"pharmaceutical":[155],"company":[156],"further":[158],"development.":[159]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-12-11T00:00:00"}